A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression

Pharmacopsychiatry

Volumn 38, Issue 1, 2005, Pages 30-35

  Otsubo, T ^a   Akimoto, Y ^a   Yamada, H ^a   Koda, R ^a   Aoyama, H ^a   Tanaka, K ^b   Mimura, M ^a   Nakagome, Kazuyuki ^a,c   Kamijima, K ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c SHOWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; NORTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; ASIAN; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSARTHRIA; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; JAPAN; JAPANESE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MICTURITION DISORDER; MOOD; NAUSEA; ONSET AGE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; REMISSION; SINGLE BLIND PROCEDURE; SLEEP DISORDER; SOMNOLENCE; STATISTICAL ANALYSIS; TACHYCARDIA; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; FLUVOXAMINE; HUMANS; JAPAN; MALE; MIDDLE AGED; NORTRIPTYLINE; PSYCHIATRIC STATUS RATING SCALES;

EID: 14044278719     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-837769     Document Type: Article

References (31)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders; 4th ed Washington DC: American Psychiatric Press, 1994
2. Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994; 8: 238-249
3. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388-397
4. Brunello N, Mendlewicz J, Kasper S, Leonard B, Montgomery S, Nelson JC et al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 2002; 12: 461-475
5. Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996; 60: 183-190
6. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 1986; 90: 131-138
7. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18: 289-299
8. Fabre L, Birkhimer LJ, Zaborny BA, Wong LF, Kapik BM. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. Int Clin Psychpharmacol 1996; 11: 119-127
9. Feighner JP, Boyer WF, Meredith CH, Hendrickson GG. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 1989; 4: 239-244
10. Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, Takahashi H, Higuchi H et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology 2003; 167: 443-448
11. Johansson I, Yue QY, Dahl ML, Heim M, Sawe J, Bertilsson L et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991; 40: 553-556
12. Kasper S, Moller HJ, Montgomery SA, Zondag E. Antidepressant efficacy in relation to item analysis and severity of depression: A placebo-controlled trial of fluvoxamine versus imipramine. Int Clin Psychopharmacol 1995; 4: 3-12
13. Lou YC, Ying L, Bertilsson L, Sjöqvist F. Low frequency of slow debrisoquine hydroxylation in native Chinese population. Lancet 1987; 2: 852-853
14. Miller MD, Pollock BG, Rifai AH, Paradis CF, Perel JM, George C et al. Longitudinal analysis of nortriptyline side effects in elderly depressed patients. J Geriatr Psychiatry Neurol 1991; 4: 226-230
15. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9: 47-53
16. Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 1995; 4: 33-40
17. Morita S, Shimoda K, Someya T, Yoshimura Y, Kamijima K, Kato N. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydorxylation of nortriptyline. J Clin Psychopharmacol 2000; 20: 141-149
18. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402-408
19. Nathan RS, Perel JM, Pollock BG, Kupfer DJ. The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. J Clin Psychiatry, 1990: 367-372
20. Ohara K, Tanabe S, Ishibashi K, Ikemoto K, Yoshida K, Shibuya H. CYP2D6 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. Eur J Clin Pharmacol 2003; 58: 659-661
21. Ottevanger EA. The efficacy of fluvoxamine in patients with severe depression. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 731-740
22. Ottevanger EA. Fluvoxamine and clomipramine in depressed and hospitalized patients: results from a randomised, double-blind study. Encephale 1995; 21: 317-321
23. Roose SP, Classman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151: 1735-1739
24. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279: 287-291
25. Roth D, Mattes J, Sheehan KH, Sheehan DV. A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 929-939
26. Spigset O, Axelsson S, Norström A, Hägg S, Dahlqvist R. The major fluvoxamine metabolite in urine is formed by CYP2D6. Eur J Clin Pharmacol 2001; 57: 653-658
27. Spigset O, Granberg K, Hägg S, Norström Å, Dahlqvist R. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol 1997; 52: 129-133
28. Walczak DD, Apter JT, Halikas JA, Borison RL, Carman JS, Post GL et al. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry 1996; 8: 139-151
29. Yoshimura R, Ueda N, Nakamura J. Low dosage of levomepromazine did not increase plasma concentrations of fluvoxamine. Int J Clin Psychopharamacol 2000; 15: 233-235
30. Yue QY, Zhong ZH, Tybring G, Dalen O, Dahl ML, Bertilsson L, Sjöqvist F. Pharmacokinetics of nortriptyline and its 10-hydroxymetablite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1998; 64: 384-390
31. Zohar J, Keegstra H, Barrelet L. Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study. Hum Psychopharmacol 2003; 18: 113-119